Advancing Animal Models for Antibacterial Drug Development –
March 5, 2020

Speakers and Panelists

Jürgen Bulitta, Ph.D.
Associate Professor
College of Pharmacy
University of Florida
Gainesville, FL

Cara Cassino, MD
Chief Medical Officer
Executive VP of Research and Development
ContraFect
Yonkers, NY

Binh Diep, Ph.D.
Associate Professor, Medicine
University of California, San Francisco
San Francisco, CA

John Farley, MD, MPH
Director (Acting)
Office of Infectious Diseases (OID)
FDA/CDER/OND
Silver Spring, MD

Tina Guina, Ph.D
CARB-X Program Manager
Biomedical Advanced Research and Development Authority (BARDA)
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Department of Health and Human Services (HHS)
Washington, D.C.

Judith Hewitt, Ph.D
Deputy Director
Office of Biodefense, Research Resources, and Translational Research
NIH/National Institute of Allergy and Infectious Diseases (NIAID)
Rockville, MD
Jennifer Hoover  
Scientific Director  
Medicine Opportunities Research Unit  
GlaxoSmithKline  
Collegeville, PA

William Hope, BMBS, Ph.D  
Chair of AMR Research  
Director of Centre of Excellence in Infectious Disease Research  
Professor, Molecular and Clinical Pharmacology, University of Liverpool  
Liverpool, UK

Abhay Joshi, Ph.D  
Pharmacology Reviewer  
Division of Infectious Disease Pharmacology (DIDP)  
Office of Clinical Pharmacology (OCP)  
FDA/CDER/OTS  
Silver Spring, MD

Marina Kozak, Ph.D.  
Biologist  
Division of CBRN Countermeasures  
HHS/ASPR/BARDA  
Washington, D.C

Matthew Lawrenz, Ph.D  
Associate Professor  
Dept. of Microbiology & Immunology  
University of Louisville  
Louisville, KY

Alexander Lepak, MD  
Assistant Professor of Medicine  
Dept. of Medicine  
University of Wisconsin – Madison  
Madison, WI

Brian Luna, Ph.D  
Assistant Professor of Molecular Biology and Immunology  
Keck School of Medicine  
University of Southern California  
Los Angeles, CA
Lynn Miesel, Ph.D  
Global Technical Director  
In-Vivo Pharmacology  
Pharmacology Discovery Services Ltd., Eurofins Panlabs, Inc.  
New York, NY

Sumathi Nambiar, MD, MPH  
Director  
Division of Anti-Infectives (DAI)  
FDA/CDER/OND/OID  
Silver Spring, MD

Eric Nuermberger, MD  
Associate Professor  
School of Medicine  
Johns Hopkins University  
Baltimore, MD

Andrew Phipps, DVM, Ph.D, DACVM  
Subject Matter Expert, Contractor  
Tunnell Government Services – Supporting Division of CBRN Countermeasures  
HHS/ASPR/BARDA  
Washington, D.C.

Kellie Reynolds, Ph.D  
Director  
Division of Infectious Disease Pharmacology (DIDP)  
FDA/CDER/OTS/OCP  
Silver Spring, MD

Simone Shurland, Ph.D  
Microbiology Reviewer  
DAI  
FDA/CDER/OND  
Silver Spring, MD

Bradley Spellberg, MD  
Chief Medical Officer, Los Angeles County-University of Southern California Medical Center  
Medical Director of Biosciences, Los Angeles, CA  
Associate Dean for Clinical Affairs, Keck School of Medicine, USC  
Los Angeles, CA
Ursula Waack, MS, Ph.D
Oak Ridge Institute for Science and Education (ORISE) Fellow
OID
FDA/CDER/OND
Silver Spring, MD

Achim Wach, Ph.D
Head DMPK/TK
Polyphor Ltd.
Allschwil, Switzerland

Thomas Walsh, MD, Ph.D.
Chief, Infectious Diseases Translational Research Laboratory
Professor of Medicine
Weill Cornell Medicine of Cornell University
New York, NY

Edward Weinstein, MD, Ph.D
Lead Medical Officer
DAI
FDA/CDER/OND/OID
Silver Spring, MD

William Weiss, MS
Director, Preclinical Services
College of Pharmacy
University of North Texas Health Science Center
Fort Worth, TX

Yuliya Yasinskaya, MD
Lead Medical Officer
DAI
FDA/CDER/OND/OID
Silver Spring, MD
Disclosures

Jürgen Bulitta received funding from NIH and FDA. Has performed consultant services for MicuRx.

Cara Cassino is a full time employee of ContraFect Corporation.

Binh Diep received research funding from NIH/NIAID, US Food and Drug Administration, Department of Defense DARPA, CARB-X, as well as Achaogen, Arsanis, AstraZeneca/MedImmune, Roche/Genentech, Integrated Biotherapeutics, Merck/Cubist, and Pfizer.

Jennifer Hoover is a full-time employee and shareholder of GlaxoSmithKline Pharmaceuticals.

William Hope holds or has recently held research grants with F2G, Astellas Pharma, Spero Therapeutics, Antabio, Allegra, Bugworks, and NAEJA-RGM. He holds awards from the Medical Research Council, National Institute of Health Research, FDA and the European Commission. William Hope has received personal fees in his capacity as a consultant for F2G, Amplyx, Auspex, Spero Therapeutics, VenatoRx, Pfizer and BLC/TAZ.

Matthew Lawrenz is a full-time employee of the University of Louisville. He receives funding support from NIH and FDA.

Alexander Lepak currently receives grant funding from NIH, Merck & Co., Inc, and MicuRx Pharmaceuticals, Inc.

Brian Luna owns equity in ExBaq.

Lynn Miesel is an employee of Eurofins Scientific.

Eric Nuermberger has no disclosures.

Brad Spellberg has received consulting fees from Merck, Shionogi, Acurx, and Klaris, and owned equity in BioAIm, ExBaq, Mycomed, and Motif in the past year.

Achim Wach is a full time employee of Polyphor Ltd. He is also a shareholder of the company.
**Thomas Walsh** has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, and Tetraphase and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Lediant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis.

**William Weiss** is a full time employee of the UNT System College of Pharmacy, a consultant for Aptorum Therapeutics and has performed sponsor funded research for ABAC Therapeutics, Achaogen, Achillion, Adenium, Affinium, Agile, Akthelia, Alcon, AmpliPhi, Amplyx, Anacor, Appili, Arietis, Arrevus, Astra Zeneca, AtoxBio, Aurasense, Auspherix, AyuVis, AzuRx, Basilea, Biolytix, BioPharmaTi, Biota, Bisortia, Biosynexus, Bioversys, Bioxiness, Cantab, Cartiledge Growth, Case Western, Cidara, Contrafect, Cubist, CUBRC, Curza, DaVolterra, DeNovaMed, DuoPhos, Entasis, eTherapeutics, Exarca, Facile Therapeutics, FCCDC, Fedora, FOB synthesis, Forge Therapeutics, Gen3Immune, Genentech, Gilead, Gladius, Gradalis, Grifols, GSK, Harvard University, InhibRx, Insmed, Janssen, Kaleido, Kalyra, Lakewood Amedex, Lead Therapeutics, LegoChem, LipoMedics, Lily Pharmaceuticals, Locus Biosciences, Macrolide Pharma, Matinas, Mattrivax, MedImmune, Melinta, Merck, Merlion, Micreos, Microbion, Mpex, Mutabilis, Nabiva, National Institute of Biotechnology Negev, NCSU, Nimbus, Novabiotech, Novacta, Novartis, Novexel, Novostar, Novozymes, Octagon, Omm Scientific, OncoNano, Oragenics, Ordway, Peptilogics, Pharmaxis, Polymedix, Polyphor, Prolysis, Purdue University, Reata, RemPex, RQx Pharmaceuticals, Secretory IgA, Seres Therapeutics, Spero Therapeutics, Stanford School of Medicine, St. Judes, Summit, Synermore, Global TB Alliance, Techulon, TenNor, Tetraphase, Thar, Theravance, Trius, UCSF, UNMC, University of Bern, Venatorx, Ventria, Vical, VicLink, Visterra, Wockhardt, Zavante, ZSPharma.